Skip to content

A novel double-stranded RNA adjuvant markedly amplifies the immunogenicity of nucleoside-modified mRNA-LNP vaccines 2256634

Jul 2026 · Journal of Immunology · Vol 215 · 0 citations

TL;DR

The dsRNA-LNP acts as a potent adjuvant for nucleoside-modified mRNA vaccination, inducing a strong immune activation, representing a potent platform for eliciting balanced, durable antiviral immunity.

Abstract

mRNA vaccines have transformed vaccinology in recent years, shortening timelines and enabling precise response to infectious diseases. One key modification that made this platform so successful is the replacement of uridine (U) with N1-methylpseudouridine (m¹ψ), which improved antigen expression and tolerability. The use of adjuvants for mRNA platforms represents a promising approach to increase immunogenicity of these vaccines, lowering the doses and offering more potent CD8+ T cell priming. However, successful adjuvant strategies remain largely undefined. Here, we developed a novel and structurally defined double-stranded RNA (dsRNA) and evaluated its immunogenic potential to induce immune responses against infectious diseases using an mRNA encoding influenza hemagglutinin (HA) as a model. C57BL/6 mice were immunized with 3 doses of HA m¹ψ mRNA-LNP (HA-LNP) alone or in co-administered with dsRNA-LNP using intramuscular-prime/ intravenous-boost administration. Peripheral blood mononuclear cells (PBMCs) were collected after each dose and stimulated ex vivo with HA peptides for intracellular cytokine staining (ICS) or ELISpot. Sera was collected 21 days after immunization for humoral analyses. Co-administration of HA-LNP and dsRNA-LNP induces more robust humoral responses with ∼3-fold higher specific IgG-antibody titers and increased neutralizing ability compared to HA-LNP alone. Evaluation of cellular arm showed that dsRNA-LNP potentializes the cellular immune responses with enhanced frequency of IFNγ production by CD4+ and CD8+ subsets, T cell activation (CD69+), CD8+ T cell polyfunctionality (IFNγ/TNFα), and higher cytotoxic profile (Granzyme B+/ Perforin+). Overall, the dsRNA-LNP acts as a potent adjuvant for nucleoside-modified mRNA vaccination, inducing a strong immune activation, representing a potent platform for eliciting balanced, durable antiviral immunity. This work was supported by the National Institute of Allergy and Infectious Disease (NIAID) and National Cancer Institute (NCI) of the US National Institutes of Health (NIH) under award numbers R01AI153064 (NP) and R01CA283736 (NP and CGR), respectively. Vaccines and Immunotherapy (VAC)

View source

Similar papers

Open access Sep 2026

Codon-dependent translation of N1-ethylpseudouridine-modified mRNA reduces innate immunity while preserving vaccine immunogenicity

Messenger RNA (mRNA) vaccines are a versatile platform for rapid vaccine development; however, nucleoside modifications must be optimized to balance translational efficiency and innate immune activation. Here, we evaluated N1-ethylpseudouridine (Et1Ψ) as an alternative to the widely used N1-methylpseudouridine (m1Ψ). E...

Jisang Park, Geonhee Lee, Haneul Lee et al. · 0 citations
Open access Aug 2026

LNP-CpG: deploy the self-adjuvant role of mRNA vaccines

With the rapid advancement of mRNA vaccines, lipid nanoparticles (LNPs) have emerged as pivotal carriers and adjuvants for non-mRNA vaccine modalities, driven by their superior nucleic acid delivery efficiency and intrinsic self-adjuvanting properties. In this study, we systematically evaluated various formulation stra...

Ning Luan, Han Cao, Xiaolong Zhang et al. · 0 citations
Review Open access Sep 2026

mRNA-based seasonal influenza vaccines: an overview of immunogenicity, efficacy, and safety

Whether mRNA platforms offer incremental benefits over enhanced formulations (such as high-dose, adjuvanted, or recombinant vaccines), which are the preferred options in some countries for older adults, remains to be established.

A. Domnich, Andrea Orsi · 0 citations
Sep 2026

LNP-formulated dbDNA™ vaccines elicit durable humoral and cellular immunity with distinct kinetics to mRNA in non-human primates.

Nucleic acid vaccines offer rapid and flexible platforms for addressing infectious diseases but achieving durable and balanced immunity remains a challenge. We evaluated a closed linear synthetic Doggybone™ DNA vaccine (dbDNA™) encoding influenza A/California/07/2009 hemagglutinin across delivery platforms and preclini...

Helen Horton, Robert F. Cunliffe, Sungwon Kim et al. · 0 citations
Aug 2026

PEGylated Polyaspartamide Nanomicelle Delivery of Self-amplifying Avian Influenza mRNA Vaccine

The avian influenza virus (AIV) poses a major threat to the poultry industry and public health worldwide, highlighting the need for effective vaccines. Currently, the influenza vaccine for human use is an inactivated vaccine produced from eggs, which requires time-consuming and safe production processes. Messenger RN...

Chin-Yu Lin, Cheng-Chung Chang, Long-Yi Chan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.